Abstract 4211
Background
To analyze patterns of failure for patients with LA-NSCLC receiving definitive chemoradiotherapy and build a nomogram for predicting the failure patterns in these patients.
Methods
Clinicopathological materials of patients between 2013 and 2016 with LA-NSCLC receiving definitive chemoradiotherapy and following-up in our hospital were collected. The endpoint was the first failure after definitive chemoradiotherapy. Based on logistic regression, the predictive value of each factor was evaluated and nomogram was built. This model was validated by ROC curve, calibration curve and decision curve analysis (DCA).
Results
With a median follow-up of 28 month, 100 patients were observed failure. Local failure and distant failure were 46 and 54, respectively. Univariate and multivariate analysis indicated that younger (p = 0.016, OR (95%CI): 0.936 (0.887-0.987)), peripheral NSCLC (p = 0.025, OR (95%CI): 2.732 (1.137-6.567)) and epidermal growth factor receptor (EGFR) mutant (p = 0.020, OR (95%CI): 3.747 (1.234-11.381)) were independent predictors of distant failure, which were included in the nomogram. ROC curve showed that area under the ROC curve (AUC) of the nomogram was 0.713, which was better than any factors along. Calibration curve revealed a satisfactory consistency between the predicted distant failure and actual observation. DCA showed most of the threshold probabilities in this model were with good net benefits.
Conclusions
We concluded that age, tumor location and EGFR mutation status could predict failure patterns in patients with LA-NSCLC receiving definitive chemoradiotherapy. A nomogram was built and validated based on these factors, showing a potential predictive value in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract